DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
ARN-509 is an investigational drug.
There have been 43 clinical trials for ARN-509. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2020.
The most common disease conditions in clinical trials are Prostatic Neoplasms, Adenocarcinoma, and Carcinoma. The leading clinical trial sponsors are National Cancer Institute (NCI), Janssen Scientific Affairs, LLC, and Aragon Pharmaceuticals, Inc.
There are forty-five US patents protecting this investigational drug and five hundred and seventy-three international patents.
Recent Clinical Trials for ARN-509
|Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland||National Cancer Institute (NCI)||Phase 2|
|Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study||National Cancer Institute (NCI)||Phase 2|
|Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study||M.D. Anderson Cancer Center||Phase 2|
Top disease conditions for ARN-509
Top clinical trial sponsors for ARN-509
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|ARN-509||Start Trial||Substituted thiohydantoin derivatives as androgen receptor antagonists||Janssen Pharmaceutica NV (Beerse, BE)||Start Trial|
|ARN-509||Start Trial||Androgen receptor modulators and uses thereof||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|ARN-509||Start Trial||Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer||Aragon Pharmaceuticals, Inc. (San Diego, CA)||Start Trial|
|ARN-509||Start Trial||Bifunctional AKR1C3 inhibitors/androgen receptor modulators and methods of use thereof||The Trustees of the University of Pennsylvania (Philadelphia, PA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|